Feed / IBRX

ImmunityBio, Inc.

IBRX

Healthcare · 7.80 -0.6% today

Partial group confirmationMarket checked 21 Aug, 15:55 GMT-4

Jodie situation report

ImmunityBio, Inc.'s move is being confirmed by its market group.

IBRX accounts for 10.9% of the group's measured movement across 6.0 effective names. raw member direction is mixed; 6 of 8 SPY-adjusted paths align to the downside. Capital-flow agreement is 15%, so confirmation is not yet clean. No verified headline preceded the measured group move.

MOVE ANATOMY

Is this move genuinely shared?

SPY-adjusted 5m paths
Role in the moveAligned contributor#6 of 8 by movement share
Group movement share10.9%Absolute path energy—not portfolio weight
Relative path-1.31%aligned
Effective breadth6.0 / 8broad
Relative alignment6/8downside path · 1 counter-moving
Capital-flow agreement15%not yet clean
SEQUENCE READ

VKTX, SMMT, ROIV moved materially before IBRX. IBRX crossed its material path threshold at 11:05 ET. BBIO, ARWR, CGON followed.

EVIDENCE COVERAGE

5 of 8 members in Gene Editing Therapies are active. 0 of 7 disclosed connections are confirming.

What would change this read
  • At least 6 of 8 durable members become active together.
  • Capital-flow agreement rises above 55%.
  • A filing-linked outsider such as RLYB begins moving with the group.

Invalidation: The live read weakens if participation falls to 2 of 8 members or fewer.

Watch this read

Who this business touches

The relationships behind IBRX

Customers, suppliers, partners and competitors named in company filings—not inferred from headlines.

Depends on

MRKMerck & Company, Inc.supplierMay 7, 2026 ▾

“This addresses a significant supply challenge: TICE BCG (Merck) has been the sole supplier of BCG product in the U.S.”

ONCBeOne Medicines AGpartnerFeb 23, 2026 ▾

“Partnership: January 2025 collaboration with BeOne.”

Depended on by

URGNUroGen Pharma Ltd.competitorMar 2, 2026 ▾

“We are aware of several pharmaceutical companies that are developing drugs in the general fields of urology and uro-oncology, such as AstraZeneca, Aura Biosciences., Bristol Myers Squibb, CG Oncology, enGene Holdings, Ferring Pharmaceuticals, Fidia Pharmaceut…”

Filing peers

IMMXIOVAMRK

Companies whose filings use similar operating language.

Open the three relationships above to see Jodie’s filing proof. Pro unlocks 5 more links, every receipt, and alerts when connected names begin moving. Unlock the full network →

What is moving around it

Live connections

IBRX is currently a Participant in the organic co-movement group Gene Editing Therapies. This group is discovered from market behaviour rather than assigned from an industry taxonomy. 3 filing-linked names are in the relationship map; none is currently confirmed as moving with the group.